‘A major step forward’: New lung cancer pill hailed as ‘off the charts’ success – with patients surviving seven times longer than those on next best treatment

Around six in ten patients given the daily tablet treated with lorlatinib survived for five years without their cancer progressing, compared to just eight per cent receiving standard care. Around six in ten patients given the daily tablet treated with lorlatinib survived for five years without their cancer progressing, compared to just eight per cent receiving standard care.